Carotech To Share Latest Human Clinical Studies on Tocomin SupraBio Product
Carotech, a regular exhibitor at SupplySide West, will continue to share with customers and visitors the latest human clinical trials of its self-affirmed GRAS, patented and bioenhanced natural full spectrum palm tocotrienol complex (Tocomin SupraBio).
17 oct 2012 --- Carotech, the largest and only GMP-certified palm tocotrienol complex producer in the world will exhibit at the SupplySide West Expo at Las Vegas from November 7-8, 2012.
The SupplySide West show is one of the most attended events focusing on healthy ingredients and products. It is the gathering place for manufacturers, researchers, marketers, as well as business decision makers for the nutraceutical and dietary supplement industry.
Carotech, a regular exhibitor at SupplySide West, will continue to share with customers and visitors the latest human clinical trials of its self-affirmed GRAS, patented and bioenhanced natural full spectrum palm tocotrienol complex (Tocomin SupraBio).
A recent published human clinical study in the Journal of Nutrition shows that tocotrienols from Tocomin SupraBio were well absorbed and significantly distributed to vital human tissues and organs, in the presence of alpha-tocopherol. This is the first ever actual tissue distribution study of tocotrienols on humans and thereby unequivocally dispelling claims that tocopherol inhibits the absorption of tocotrienols.
The same study also reported oral consumption of Tocomin SupraBio delayed the progress of end stage liver disease. This was evident from the significantly reduced Model for End Stage Liver Disease (MELD) Scores in patients who were scheduled for liver transplant, when compared to subjects supplemented with alpha-tocopherol (the regular form of vitamin E). Another related interesting human clinical trial is on Tocomin SupraBio and non-alcoholic fatty liver disease (NAFLD), which has just been completed and pending publication. In America alone, there is nearly a third of the US population (approx. 120 million people) have NAFLD, which at the moment, has no cure and has been documented as the precursor for metabolic syndrome diseases such as Diabetes, Obesity and Hypertension. Childhood obesity is also a major health problem associated with an increase in the prevalence and severity of nonalcoholic fatty liver disease.
In addition, researchers from the University Science of Malaysia has recently completed a randomized, double-blind, placebo-controlled clinical trial in human volunteers who have white matter lesions, with the aim to compare lesion volumes before and after supplementation of either Tocomin SupraBio or placebo. The researchers used Magnetic Resonance Imaging (MRI) to detect the occurrence and volume of white matter lesions. White matter lesions are subclinical areas of brain damage strongly associated with established cardiovascular risk factors and is an independent risk factor for stroke. This clinical study, the largest ever trial specifically on tocotrienols, has been submitted and pending publication in a peer-reviewed journal. The results are encouraging with significant positive outcome.
“More recently, researchers at the Ohio State University Medical Center have announced the commencement of another large scale human clinical trial on neuroprotection. The “NUTRITION” Trial (Natural Tocotrienol Against Ischemic Stroke Event) aims to study the potential of Tocomin SupraBio in reducing the risk for stroke through mitigating important stroke risk factors ,” says Mr. Bryan See, Regional Product Manager, Carotech Inc.
